Avelumab in Merkel Cell Carcinoma: Prognosis and Treatment After Progression

From General Health to Occupational Exposure Concerns

Public awareness of general health and science has long centered on foundational wellness principles—routine screenings, lifestyle factors, and broad disease prevention. This legacy framework provides a baseline understanding of how the body responds to external stressors, including environmental and pharmaceutical agents. Within this context, the immune system’s role in recognizing and eliminating aberrant cells is a familiar concept, often discussed in relation to vaccines or cancer surveillance. As we shift focus toward more specialized therapeutic landscapes, the same underlying logic applies: certain biological pathways can be modulated to enhance immune activity against malignancies. This is particularly relevant when considering targeted immunotherapies, such as Avelumab, which are designed to restore immune function in specific oncological settings. The transition from general health education to occupational exposure concern emerges when we examine the populations most likely to encounter such agents. In mass production environments, workers may handle pharmaceutical compounds or their precursors, raising questions about unintended exposure. While the therapeutic use of Avelumab is carefully controlled, the potential for occupational contact—through inhalation, dermal absorption, or accidental ingestion—introduces a distinct risk profile. This concern is amplified when considering Merkel cell carcinoma, a rare but aggressive skin cancer linked to immune suppression and viral factors. Thus, the bridge from general health literacy to occupational hazard assessment requires a careful evaluation of exposure pathways, without overstating mechanistic certainty.

Avelumab: Mechanism and Clinical Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/33439294/). This approval marked avelumab as the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic ultraviolet light exposure and the Merkel cell polyoma virus, and it carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The clinical presentation of MCC typically involves a rapidly growing, painless, firm, red or purple nodule on sun-exposed skin, often on the head, neck, or extremities. Diagnosis is confirmed through histopathological examination and immunohistochemical staining for neuroendocrine markers such as cytokeratin 20 and chromogranin A. Staging involves imaging to assess for metastatic spread, as MCC frequently metastasizes to lymph nodes, liver, lungs, and bone.

Efficacy and Immune-Related Adverse Events

The approval of avelumab for metastatic MCC was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200 (https://pubmed.ncbi.nlm.nih.gov/29799096/). In Part A of this study, confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Avelumab functions by blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby reactivating antitumor immune responses. This mechanism can lead to overactivation of the immune system, resulting in immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported adverse effects include a range of irAEs such as dermatitis, colitis, hepatitis, pneumonitis, endocrinopathies, and, as documented in a case report, hypercalcemia due to reactivation of sarcoidosis (https://pubmed.ncbi.nlm.nih.gov/31543781/). In that case, hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). The adequacy of warnings regarding avelumab and MCC is reflected in product labeling and clinical guidelines, which detail the risk of irAEs and the need for monitoring. However, the specific risk of sarcoidosis reactivation is not commonly highlighted, and clinicians should be aware of this potential complication.

Treatment Options After Avelumab Progression

For patients who become refractory to avelumab, treatment options are limited. In Europe, approved systemic therapies for metastatic MCC are restricted to avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). For avelumab-refractory patients, combined therapy with ipilimumab and nivolumab (IPI/NIVO) has shown activity. In a retrospective study of five patients treated at three academic sites in Germany, three out of five patients responded to combined IPI/NIVO according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG further supported the efficacy of ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study confirmed that immune checkpoint inhibitors offer durable responses and significant clinical benefit, with avelumab and pembrolizumab approved by the U.S. Food and Drug Administration for advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). Prognosis-related considerations for patients treated with avelumab are influenced by several factors. The timeline between exposure to avelumab and documented harm varies. Immune-related adverse events can occur at any time during treatment, sometimes weeks to months after initiation. In the case of sarcoidosis reactivation, hypercalcemia developed during avelumab therapy and was managed without discontinuation (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who progress on avelumab, the prognosis is poor, as efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). However, salvage therapy with ipilimumab plus nivolumab may offer benefit in a subset of patients (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). The overall prognosis for metastatic MCC remains guarded, with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism of action of avelumab in Merkel cell carcinoma?

Avelumab is a fully human IgG1 monoclonal antibody that targets programmed cell death ligand 1 (PD-L1) on tumor cells, blocking its interaction with PD-1 on T cells. This reactivates antitumor immune responses, allowing the immune system to recognize and attack Merkel cell carcinoma cells (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the treatment options for patients with Merkel cell carcinoma who progress on avelumab?

For patients who become refractory to avelumab, treatment options are limited. In Europe, avelumab is the only approved systemic therapy for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/33439294/). However, retrospective studies suggest that combined therapy with ipilimumab and nivolumab may be effective in a subset of avelumab-refractory patients (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.